115608-07-6 Usage
Molecular structure
1-Butanone derivative with a quinoline ring and a 2-methylphenylamino group
The compound is derived from 1-butanone and features a quinoline ring structure with an attached 2-methylphenyl group connected to an amino group.
Potential applications
Pharmaceutical industry
Due to its structural similarities to other bioactive molecules, it may exhibit pharmacological activity and be used in the development of new drugs.
Use in organic synthesis
As a research tool
The compound may be utilized in organic synthesis processes and serve as a research tool for chemical and biological studies.
Further research and development
Required for specific properties and potential uses
The compound's specific properties and potential applications depend on ongoing research and development in the fields of chemistry and biology.
Solubility
Unknown (requires experimental data)
The solubility of the compound in various solvents is not provided and would need to be determined through experimentation.
Stability
Unknown (requires experimental data)
The stability of the compound under different conditions (e.g., temperature, pH, etc.) is not provided and would need to be determined through experimentation.
Reactivity
Unknown (requires experimental data)
The reactivity of the compound with other chemicals and its potential to undergo various chemical reactions is not provided and would need to be determined through experimentation.
Check Digit Verification of cas no
The CAS Registry Mumber 115608-07-6 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 1,1,5,6,0 and 8 respectively; the second part has 2 digits, 0 and 7 respectively.
Calculate Digit Verification of CAS Registry Number 115608-07:
(8*1)+(7*1)+(6*5)+(5*6)+(4*0)+(3*8)+(2*0)+(1*7)=106
106 % 10 = 6
So 115608-07-6 is a valid CAS Registry Number.
115608-07-6Relevant academic research and scientific papers
Reversible inhibitors of the gastric (H+/K+)-ATPase. 4. Identification of an inhibitor with an intermediate duration of action
Leach,Brown,Ife,Keeling,Parsons,Theobald,Wiggall
, p. 2748 - 2762 (2007/10/03)
3-Acyl-4-(arylamino)quinolines were previously identified as gastric (H+/K+)-ATPase inhibitors, and clinical efficacy has been demonstrated for compound 3 (SK and F 96067). In the present study the further structure- activity relatio
Reversible inhibitors of the gastric (H+/K+)-ATPase. 3. 3-Substituted-4- (phenylamino)quinolines
Ife,Brown,Keeling,Leach,Meeson,Parsons,Reavill,Theobald,Wiggall
, p. 3413 - 3422 (2007/10/02)
Previously, gastric (H+/K+)-ATPase inhibitors such as 2 have been prepared as analogues of 1a on the presumption that the 3-carbethoxy substituent plays a key role in establishing the orientation of the 4- arylamino group. In this paper we explore further the contribution made to activity by the quinoline 3-substituent. We show that, for compounds bearing such a substituent, only a particular combination of properties provides high activity, both in vitro and as inhibitors of gastric acid secretion in vivo. The ability of the substituent to affect activity by restricting rotation about the C(quin)-N bond through a combination of both a π-electron withdrawal and hydrogen bonding is supported by the current study. However, high activity is only achieved if the effect of this group on the quinoline pK(a) is kept to a minimum. 3-Acyl substituents provide an optimum combination of electronic properties. From this series, compound 17c (SK and F 96067) was shown to be a potent inhibitor of histamine-stimulated gastric acid secretion after oral dosing in the Heidenhain pouch dog and was selected for further development and evaluation in man.
